Immune-based Therapies
P14/ARF-Positive Malignant Pleural Mesothelioma: A Phenotype With Distinct Immune Microenvironment
Frontiers in Oncology 2021 March 22 [Link] Federica Pezzuto, Francesca Lunardi, Luca Vedovelli, Francesco Fortarezza, Loredana Urso, Federica Grosso, Giovanni Luca Ceresoli, Izidor Kern, Gregor Vlacic, Eleonora Faccioli, Marco Schiavon, Dario Gregori, Federico Rea, Giulia Pasello, Fiorella Calabrese Abstract Introduction: The CDKN2A gene plays a central role in the pathogenesis of malignant pleural mesothelioma (MPM).…
Read MoreNF2 and Canonical Hippo-YAP Pathway Define Distinct Tumor Subsets Characterized by Different Immune Deficiency and Treatment Implications in Human Pleural Mesothelioma
Cancers 2021 March 29 [Link] Haitang Yang, Sean R R Hall, Beibei Sun, Liang Zhao, Yanyun Gao, Ralph A Schmid, Swee T Tan, Ren-Wang Peng, Feng Yao Abstract (1) Inactivation of the tumor suppressor NF2 is believed to play a major role in the pathogenesis of malignant pleural mesothelioma (MPM) by deregulating the Hippo-YAP signaling…
Read MoreEliminating mesothelioma by AAV-vectored, PD1-based vaccination in the tumor microenvironment
Molecular Therapy Oncolytics 2021 January 21 [Link] Zhiwu Tan, Mei Sum Chiu, Chi Wing Yan, Kwan Man, Zhiwei Chen Abstract The potency of cancer vaccines is often compromised by a variety of immunoinhibitory mechanisms, including stimulation of the programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) immune checkpoint pathway. Here, to overcome inhibition,…
Read MoreSerum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial
Lung Cancer 2021 January 14 [Link] Sharyn I Katz, Leonid Roshkovan, Ian Berger, Joseph S Friedberg, Evan W Alley, Charles B Simone 2nd, Andrew R Haas, Keith A Cengel, Daniel H Sterman, Steven M Albelda Abstract Objectives: Soluble mesothelin-related protein (SMRP) and fibulin-3 serum levels may serve as diagnostic and prognostic biomarkers of malignant pleural…
Read MoreHigh-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients
European Journal of Cancer 2020 December 13 [Link] Luca Cantini, Federica Pecci, Daan P Hurkmans, Robert A Belderbos, Andrea Lanese, Cecilia Copparoni, Sophie Aerts, Robin Cornelissen, Daphne W Dumoulin, Ilaria Fiordoliva, Silvia Rinaldi, Joachim G J V Aerts, Rossana Berardi Abstract Background: In preclinical models, statins showed vaccine adjuvant activities and synergized with PD-1 inhibitors.…
Read MoreImmunotherapy for mesothelioma: rationale and new approaches
Clinical Advances for Hematology and Oncology 2020 September [Link] Joshua E Reuss, Patrick M Forde Abstract Therapeutic advancement for mesothelioma has been stagnant, with minimal treatment innovation in the past decade. Recently, however, immune checkpoint blockade (ICB) targeting the programmed death 1 and cytotoxic T-lymphocyte-associated antigen 4 pathways has revolutionized the treatment of multiple malignancies…
Read MoreAXL Inactivation Inhibits Mesothelioma Growth and Migration via Regulation of p53 Expression
Cancers 2020 September 25 [Link] Wei Song, Hao Wang, Minmin Lu, Xinxin Ni, Nacef Bahri, Shuihao Zhu, Limin Chen, Yuehong Wu, Jieqiong Qiu, Jonathan A Fletcher, Wen-Bin Ou Abstract Malignant mesothelioma is a locally aggressive and highly lethal neoplasm. Dysregulation and activation of Gas6/AXL tyrosine kinase signaling are associated with mesothelioma progression, but the mechanisms…
Read MoreA multicentre randomised phase III trial comparing pembrolizumab vs single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
Annals of Oncology 2020 September 22 [Link] S Popat, A Curioni-Fontecedro, U Dafni, R Shah, M O’Brien, A Pope, P Fisher, J Spicer, A Roy, D Gilligan, O Gautschi, E Nadal, W D Janthur, R López Castro, R García Campelo, S Rusakiewicz, I Letovanec, V Polydoropoulou, H Roschitzki-Voser, B Ruepp, A Gasca-Ruchti, S Peters, R…
Read MoreFoxp3 + Regulatory T Cell Depletion after Nonablative Oligofractionated Irradiation Boosts the Abscopal Effects in Murine Malignant Mesothelioma
Journal of Immunology 2020 September 18 [Link] Mikihiro Kohno, Junichi Murakami, Licun Wu, Mei-Lin Chan, Zhihong Yun, B C John Cho, Marc de Perrot Abstract Increasing evidence indicates that local hypofractionated radiotherapy (LRT) can elicit both immunogenic and immunosuppressive local and systemic immune responses. We thus hypothesized that blockade of LRT-induced immunosuppressive responses could augment…
Read MorePhase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin
Cancer 2020 September 1 [Link] Raffit Hassan, Christine Alewine, Idrees Mian, Anna Spreafico, Lillian L Siu, Carlos Gomez-Roca, Jean-Pierre Delord, Antoine Italiano, Ulrik Lassen, Jean-Charles Soria, Rastilav Bahleda, Anish Thomas, Seth M Steinberg, Cody J Peer, William D Figg, Gerhard Niederfellner, Valérie Méresse Naegelen, Ira Pastan Abstract Background: LMB-100 is an antibody-toxin conjugate with an…
Read More